Fate Therapeutics Inc (FATE) : Board Of Trustees Of The Leland Stanford Junior University reduced its stake in Fate Therapeutics Inc by 1.76% during the most recent quarter end. The investment management company now holds a total of 285,953 shares of Fate Therapeutics Inc which is valued at $454,665 after selling 5,114 shares in Fate Therapeutics Inc , the firm said in a disclosure report filed with the SEC on May 12, 2016.Fate Therapeutics Inc makes up approximately 0.07% of Board Of Trustees Of The Leland Stanford Junior University’s portfolio.
Other Hedge Funds, Including , Spark Investment Management boosted its stake in FATE in the latest quarter, The investment management firm added 1,100 additional shares and now holds a total of 63,700 shares of Fate Therapeutics Inc which is valued at $101,283. Fate Therapeutics Inc makes up approx 0.01% of Spark Investment Management’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in FATE in the latest quarter, The investment management firm added 27,578 additional shares and now holds a total of 69,394 shares of Fate Therapeutics Inc which is valued at $110,336.Blackrock Fund Advisors reduced its stake in FATE by selling 4,740 shares or 7.34% in the most recent quarter. The Hedge Fund company now holds 59,871 shares of FATE which is valued at $95,195. Nationwide Fund Advisors added FATE to its portfolio by purchasing 22,578 company shares during the most recent quarter which is valued at $38,608.
Fate Therapeutics Inc opened for trading at $1.53 and hit $1.57 on the upside on Friday, eventually ending the session at $1.51, with a gain of 1.22% or 0.0182 points. The heightened volatility saw the trading volume jump to 1,30,822 shares. Company has a market cap of $44 M.
Fate Therapeutics Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company’s development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)) which targets Hematologic Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II Phase Ib and Phase Ib respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB) which is for Hematologic and Malignancies therapeutic area and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.